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Background: Cervical lymph node metastases in papillary thyroid cancer are common. Although central neck
dissection is indicated in clinically nodal-positive disease, it remains controversial in patients with no clinical
evidence of nodal metastasis. The aim of this retrospective study was to determine the outcomes of clinically lymph
node-negative patients with papillary thyroid cancer who underwent total thyroidectomy without a central neck
dissection, in order to determine the rates of recurrence and reoperation in these patients compared with a group
of patients submitted to total thyroidectomy with central neck dissection.
Methods: Two-hundred and eighty-five patients undergoing total thyroidectomy with preoperative diagnosis of
papillary thyroid cancer, in the absence of suspicious nodes, were divided in two groups: those who underwent a
thyroidectomy only (group A; n = 220) and those who also received a central neck dissection (group B; n = 65).
Results: Six cases (2.1%) of nodal recurrence were observed: 4 in group A and 2 in group B. Tumor histology was
associated with risk of recurrence: Hürthle cell-variant and tall cell-variant carcinomas were associated with a high
risk of recurrence. Multifocality and extrathyroidal invasion also presented a higher risk, while smaller tumors were
at lower risk.
Conclusions: The role of prophylactic central lymph node dissection in the management of papillary thyroid
cancer remains controversial. Total thyroidectomy appears to be an adequate treatment for clinically node-negative
papillary thyroid cancer. Prophylactic central neck dissection could be considered for the more appropriate selection
of patients for radioiodine treatment and should be reserved for high-risk patients only. No clinical or pathological
factors are able to predict with any certainty the presence of nodal metastasis. In our experience, tumor size, some
histological types, multifocality, and locoregional infiltration are related to an increased risk of recurrence. The
potential use of molecular markers will hopefully offer a further strategy to stratify the risk of recurrence in patients
with papillary thyroid cancer and allow a more tailored approach to offer prophylactic central neck dissection to
patients with the greatest benefit. Multi-institutional larger studies with longer follow-up periods are necessary to
draw definitive conclusions.
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Papillary thyroid carcinoma (PTC) is the most common
thyroid malignancy, comprising approximately 90% of
new cases of thyroid cancer in iodine-sufficient areas of
the world [1-6]. Patients with PTC have an excellent
prognosis, with 10-year survival rates exceeding 90%
[1,2,4,6,7]. Total thyroidectomy (TT) is generally ac-
cepted as the procedure of choice for all PTC exceeding
10 mm in diameter [1,2,8].
Despite the excellent prognosis, cervical lymph node
metastases are common, occurring in 20 to 50% of pa-
tients [1,2,6,8-14]. Micrometastases are even more com-
mon and may be found in 90% of patients [9-11,14,15].
The most common sites of metastases are the central neck
lymph nodes (level VI) [1,2,6,9,12,16-18]. Nodal metasta-
ses are associated with an increase in recurrence rate and
may impact negatively on survival [2,9,11,19,20].
Although central neck dissection is indicated in cli-
nically nodal-positive disease, it remains controversial in
patients with no clinical evidence of nodal metastasis
[5,21].
Some authors recommend routine central neck dissec-
tion in order to prevent a future recurrence, citing the
high risk of positive lymph nodes, the accuracy of staging,
better outcomes, reduced postoperative thyroglobulin (Tg)
levels, and a lower morbidity rate associated with the first
operation [14,15,18,19,22-26], whereas others suggest that
this procedure increases the risk of injury to parathy-
roid glands and recurrent laryngeal nerves, without
any demonstrable benefits in terms of long-term
survival [2,10,11,15,18,22,23,27,28].
Because of the risk of complications following prophy-
lactic central neck dissection, recently several authors
have introduced a more limited (ipsilateral) central neck
dissection, as an alternative treatment for patients with
unilateral PTC [20,25,29].
The aim of this retrospective study was to determine
the outcomes of clinically lymph node- negative patients
with PTC who underwent total thyroidectomy without a
central neck dissection, in order to determine the rates
of recurrence and reoperation in these patients com-
pared with a group of patients submitted to total
thyroidectomy with central neck dissection.
Methods
The clinical records of patients undergoing total thyroid-
ectomy with or without prophylactic lymphadenectomy,
between 2002 and 2010, presenting preoperative cyto-
logical evidence of PTC but no signs of enlarged lymph
nodes during preoperative ultrasonography and intraop-
erative inspection and palpation were analyzed. In our
unicenter retrospective study, 285 consecutive PTC
patients were identified by computerized search. These
patients had undergone TT with curative intent in ourDepartment of Surgical Sciences at the University of
Cagliari. The data were collected from retrospective
chart review. Patients were divided into two groups:
those who had received a thyroidectomy without central
neck dissection (group A; n = 220), and those who had
received a thyroidectomy with central neck dissection
(group B; n = 65). These patients were considered for
central neck dissection on the basis of the surgeon’s
judgment of the surgical field, macroscopic appearance
of the tumor, tumor size, and suspicion of extra-capsular
invasion. In all cases, surgery was performed by three
experienced endocrine surgeons. For each patient, a
preoperative diagnosis of PTC had been obtained by
ultrasound (US)-guided fine-needle aspiration cytology
(FNAC). The preoperative work-up consisted of free
thyroid hormone (FT3, FT4), thyrotropin (TSH), Tg and
anti-Tg antibody (TgAb) measurements, and high re-
solution US of the neck by a skilled sonographer. A
pre- and postoperative fibrolaryngoscopy was routinely
performed in all patients. Postoperative diagnosis of
lymph node recurrence was performed by US-guided
FNAC and Tg measurement in FNAC fluid wash-out
(FNAC-Tg) in the case of enlarged lymph nodes ≥ 1 cm.
Patient demographics and postoperative complications
were recorded, including neck hematomas requiring
reoperation, transient or permanent hypoparathyroidism,
transient or permanent vocal cord palsy, and distant and
locoregional recurrence detected by postoperative sur-
veillance. Hypoparathyroidism (defined as a parathyroid
hormone (PTH) level < 10 pg/ml; normal values range
between 10 to 65 pg/ml) was considered permanent
when it lasted for more than six months. Permanent re-
current laryngeal nerve injury was defined as vocal fold
paralysis, confirmed with laryngoscopic examination,
persisting for more than six months. Qualitative data
were expressed as percentages, while quantitative data
were expressed as the mean value ± standard deviation.
The study was approved by the Institutional Ethical
committee of the University of Cagliari.
Biochemical assays
FT3, FT4, and TSH were determined by automatic ultra-
sensitive chemiluminescent assays (Ortho Clinical Diag-
nostic SpA, Milan, Italy). Tg and TgAb were detected by
chemiluminescent assays (Immulite 2000, Diagnostic
Products Corporation, Los Angeles, CA, USA; distribu-
tor Medical Systems Corporation, Genoa, Italy).
Surgery
All operations were performed by the same three sur-
geons, thus the TT and lymph node dissection tech-
niques used were consistent across patients. Recurrent
laryngeal nerves were routinely identified and exposed
up until their insertion in the larynx, and parathyroid
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pected devascularized or incidentally removed para-
thyroid glands, a muscular autoimplantation followed.
Serum calcium and intact parathyroid hormone levels
were assayed on the first postoperative day, and subse-
quently on the basis of a clinical evaluation.
Follow-up
Patient follow-up examinations consisted of neck USs
and the monitoring of serum Tg and TgAb levels every
six months during suppressive L-thyroxine treatment. A
serum Tg level ≤ 0.2 ng/ml was taken as undetectable.
Surveillance for possible recurrence in patients consid-
ered disease-free was achieved by Tg detection or, in
those positive for TgAb, by whole-body 131I scanning
after recombinant human thyrotropin (rhTSH) stimula-
tion and neck US. Diagnosis of disease recurrence in the
cervical lymph nodes was based on US-guided FNC, Tg
washing of FNC aspirates, and serum Tg level monitor-
ing. The median length of follow-up was 100 months
(range 38 to 137 months).
Statistical analysis
Data were analyzed using descriptive statistics: for
categorical variables, the Pearson’s chi-squared (exact)
test was used; for quantitative variables independent Stu-
dent’s t-tests were used. Data were reported as the mean
value ± standard error of the mean (SEM). All calcula-
tions were performed using the software package SPSS
15.0 for Windows (SPSS Inc., Chicago, IL, USA). Com-
parisons were considered statistically significant for
P < 0.05.Table 1 Demographic and pathological data of 285 papillary
Total
Patients 285
Male 60 (21.05%)
Female 225 (78.94%)
Mean age (years) 51.54 ± 16.39
Histology
Papillary classic 178 (62.45%)
Follicular-variant 86 (30.17%)
Hürthle cell-variant 9 (3.15%)
Tall cell-variant 12 (4.21%)
Tumor
Mean size (mm) 16.39 ± 11.19
Unique 205 (71.92%)
Multifocal 80 (28.07%)
Microcarcinoma 57 (20%)
Locoregional infiltration 73 (25.61%)Results
Between September 2002 and December 2010, 285 PTC
patients, 225 women and 60 men (F/M ratio = 3.75/1),
with a median age of 51.5 years (range 18 to 81), were
submitted to TT. Group A consists of 220 patients, 172
female and 48 male (F/M ratio = 3.58/1) with a median
age of 53 years (range 18 to 81), who were submitted to
TT without lymphadenectomy. Group B consists of 65
patients, 53 female and 12 male (F/M ratio = 4.41/1)
with a median age of 46 years (range 20 to 77), who
were submitted to TT with prophylactic central neck bi-
lateral lymphadenectomy (see Table 1). Median nodal
yield for patients undergoing central neck dissection was
7.5. A neck hematoma, requiring surgical re-exploration
was observed in 3 patients (1.05%): 2 in group A (0.9%)
and one in group B (1.53%) (P = 0.79). Transient or
definitive hypoparathyroidism was observed in 55 (25%)
and 10 patients (4.54%), respectively, in group A; while
25 (38.46%) and 7 patients (10.76%) were diagnosed in
group B, respectively (P = 0.049 and 0.117). Temporary
recurrent laryngeal nerve paralysis was observed in 3
patients in group A (1.36%) and in 2 patients in group B
(3.07%) (P = 0.69). No cases of permanent or bilateral
recurrent laryngeal paralysis were observed (see Table 2).
Pathological data
Median tumor size was 16 mm (16 mm in group A and
17 mm in group B). A microcarcinoma (<1 cm) was di-
agnosed in 57 patients (20%): 47 in group A (21.36%)
and 10 in group B (15.38%). The histotype was classic
papillary in 178 patients (62.45%, 134 in group A and 44
in group B), follicular-variant in 86 (30.17%, 71 in groupthyroid cancer patients
Group A Group B P
220 65
48 (21.81%) 12 (18.46%) 0.681
172 (78.18%) 53 (81.53%)
53.07 ± 13.9 46.36 ± 14.73 0.0008
134 (60.9%) 44 (67.69%) 0.025
71 (32.27%) 15 (23.07%)
9 (4.09%) 0
6 (2.72%) 6 (9.23%)
16.13 ± 11.82 17.27 ± 8.77 0.47
160 (72.72%) 45 (69.23%) 0.001
60 (27.27%) 20 (30.76%)
47 (21.36%) 10 (15.38%) 0.2686
46 (20.9%) 27 (41.53%) 0.001
Table 2 Total thyroidectomy: complications
Total Group A Group B P
Temporary hypoparathyroidism 80 (28.07%) 55 (25%) 25 (38.46%) 0.049
Permanent hypoparathyroidism 17 (5.96%) 10 (4.54%) 7 (10.76%) 0.117
Temporary unilateral vocal cord palsy 5 (1.75%) 3 (1.36%) 2 (3.07%) 0.698
Permanent unilateral vocal cord palsy 0 0 0 -
Bilateral vocal cord palsy 0 0 0 -
Neck hematoma 3 (1.05%) 2 (0.9%) 1 (1.53%) 0.798
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all in group A) and tall cell-variant in 12 (4.21%, 6 in
group A and 6 in group B). Eighty patients (28.07%) had
multifocal tumors: 60 in group A (27.27%) and 20 in
group B (30.76%). Seventy-three patients (25.61%) had a
locoregional infiltration (T3): 46 in group A (20.9%) and
27 in group B (41.53%) (see Table 1).
The two groups were well matched for sex, histology,
tumor size, and radioiodine treatment; while the median
age was slightly higher in group A, multifocality and
locoregional infiltration were most represented in group
B and incidence of microcarcinomas was most repre-
sented in group A. In group B, metastases were found in
17 patients (26.15%) and nodal micrometastases in 3
cases (4.61%). The median number of removed lymph
nodes was 7.5. In patients with metastases, the median
number of metastatic nodes was 3.5.
Radioiodine ablation
After surgery, 259 patients (90.87%) underwent adjuvant
radioiodine ablation (1,850 to 3,700 MBq-131I). Apart
from lymph node involvement, indications for postoper-
ative 131I treatment were: a tumor > 1 cm, extra-capsular
thyroid invasion or locoregional extension, unfavorable
histological subtype (follicular, diffuse sclerosing, or tall
cell-variant papillary cancer), multifocal disease, or BRAF-
positive tumor specimens. Twenty-six patients (9.12%)
with tumor < 1 cm and without risk factor (lymph node
involvement, extra-capsular invasion, unfavorable histo-
logical subtype, multifocal disease, or BRAF-positive) were
not submitted to adjuvant radioiodine ablation. To obtain
adequate levels of endogenous TSH (>30 mU/ml), that are
associated with an increased radioiodine uptake, patients
stopped L-T4 replacement three to four weeks before
radioiodine treatment; when L-T4 withdrawal was not
indicated, TSH stimulation was achieved using rhTSH
(Thyrogen®, Genzyme, USA), according to standard proto-
cols. Post-therapy whole-body scanning was performed
four to seven days after radioiodine treatment.
Radioiodine ablation was performed in 194 patients in
group A and all 65 patients in group B. In five patients
of group B, two or more radioiodine administrations
were needed; in all the other patients only one radioio-
dine administration was performed. Differences betweenthe two groups were not statistically significant (P = 0.476).
Median dose administered was 2,420 MBq-131I in group
A and 2,600 MBq-131I in group B; so prophylactic neck
dissection did not statistically correlate with radioiodine
dose.
Median postoperative stimulated thyroglobulin was
1.0 ng/ml in group A and 1.2 in group B. This value was
not used to determine radioiodine dose given the slight
difference between the two groups.
Recurrence
No patient developed distant recurrence during follow-
up. After TT and radioiodine ablation, ipsilateral nodal
(III to IV) recurrence was observed in 6 cases (2.1%): 4
in group A (1.81%) and 2 in group B (3.07%) (P = 0.89).
Only one central (VI) node recurrence was observed in
group A (0.45%). The demographic characteristics of
patients with recurrence were the following: 2 male
(47 and 34 years) and 4 females (median age 57.5 years;
range 34 to 69). The mean elapsed time between inter-
vention and lymph node recurrence was 15 months in
group A (range 6 to 24) and 7.5 months in group B (6
and 9). Two patients had classic-variant, 1 had follicular-
variant, 1 Hürthle cell-variant and 2 patients had tall
cell-variant papillary carcinomas. In particular, this last
variant was strongly associated with recurrence (P = 0.001;
Table 3). Locoregional infiltration and multifocality were
also associated to risk of recurrence (P = 0.005 and 0.009,
respectively; Table 3). In all cases, a lateral and central
lymph node dissection was performed, followed by
another session of radioiodine ablation. Median number
of removed nodes was 4; median number of metastatic
nodes was 2.5. No complications were observed after
reoperation.
Discussion
Lymph node metastases in level VI nodes in PTC are
common, with macroscopically positive gross nodal dis-
ease being present in 10 to 30% of patients [10,30,31],
while the incidence of clinically non-palpable disease is
reported in 40 to 70% of patients [10,19,32]. However,
the management and impact on the prognosis of this
form of lymph node metastasis is unclear [10]. Nodal
involvement in PTC has been shown in a number of
Table 3 Risk factors of recurrence: gender, age and
histology
Recurrence P
Gender
Male 2/60 (3.33%) 0.81
Female 4/225 (1.77%)
Mean age 49.83 ± 15.58
(versus 51.58 ± 14.35 non-recurrent)
0.768
Histology P = 0.001
Papillary classic 2/178 (1.12%)
Follicular-variant 1/86 (1.16%)
Hürthle cell-variant 1/9 (11.11%)
Tall cell-variant 2/12 (16.66%)
Tumor
Mean size 22.5 ± 6.62
(versus 16.26 ± 11.24 non-recurrent)
0.177
Unique 1/205 (0.48%) 0.009
Multifocal 5/80 (6.25%)
Locoregional infiltration 0.005
Present 5/73 (6.84%)
Absent 1/212 (0.47%)
Calò et al. World Journal of Surgical Oncology 2014, 12:152 Page 5 of 8
http://www.wjso.com/content/12/1/152retrospective studies to be associated with an increased
risk of locoregional recurrence but not with overall
survival [2,10,22,33,34]. Some studies support the concept
that microscopically positive lymph nodes do not appear
to progress to recurrence whether or not they are re-
moved [24,25]. Other reports indicate that nodal dissec-
tion in differentiated thyroid cancer can advantageously
decrease locoregional recurrence and improve survival
[2,10,22,34]. Arguments in favor of prophylactic central
node dissection are: the high incidence of lymph node me-
tastases; the insufficient diagnostic accuracy of ultrasonog-
raphy and intraoperative exploration in 1/3 of PTC; and
the failure of 131I ablation in about 30% of cases, especially
when enlarged lymph nodes greater than 1 cm are present
[10,23,28].
High resolution cervical US is the most sensitive
method for detecting metastatic lymph nodes as small as
2 to 3 mm. Unfortunately, although US has a high sensi-
tivity and specificity in detecting lateral lymph node
metastasis, it is less useful in the central compartment
when the thyroid gland is still present [7,24,35,36].
Preoperative ultrasonography have high specificity and
positive predictive value, but low sensitivity (40 to 70%)
and negative predictive value (of only about 61%) for the
detection of lymph node metastases in the central neck
compartment [2,6,26,28]. Intraoperative clinical assess-
ment of lymph nodes is also inaccurate and can be
confounded by the presence of enlarged nodes related to
Hashimoto’s thyroiditis [24].Central node dissection increases the number of pa-
tients with undetectable Tg levels [10]. For example, one
study found that the number of patients with basal Tg
serum levels < 0.2 ng/ml during L-thyroxine suppression
therapy was significantly higher among those who had
undergone prophylactic central neck dissection [2]. In-
deed, the addition of central lymph node dissection to
total thyroidectomy is repeatedly reported to decrease
serum levels of Tg and increase the rates of undetectable
Tg [1,14,16]. Our experience does not confirm these
data.
Another argument in favor of prophylactic central
neck dissection is the lower associated rates of morbidity
compared to those associated with reoperation [10,37].
Reoperative central lymph node dissection is more chal-
lenging and puts the recurrent laryngeal nerve and para-
thyroid glands at increased risk [17,26] due to increased
scar tissue, edema and friability of the tissues together
with distortion of the landmarks [38]; reoperative sur-
gery has also been associated with a higher risk of post-
operative hematoma [39].
A prophylactic central lymphadenectomy permits a
better staging of central neck compartment lymph nodes,
but further benefits remain to be demonstrated [10].
Authors report a 30% increase in the number of pa-
tients with T1 PTC (preoperatively considered to be
N0), for whom 131I ablation was indicated following rou-
tine central and lateral nodal dissection demonstrating un-
expected nodal metastases. The rational for this approach,
in patients with tumors < 1 cm, is that positive lymph
nodes are an indication for radioiodine ablation [10].
Lymphadenectomy seems to play a role in staging and
may therefore be indicated when radioactive treatment
would not normally be administered. When radioiodine
treatment is advisable, routine lymph node dissection does
not modify the treatment protocol, and is, therefore, not
indicated [10]. Recent studies have suggested that approxi-
mately one-third of patients who have prophylactic central
neck dissection may be upstaged [2,37], and as a conse-
quence radioiodine therapy is used significantly more
frequently in these patients [2]. Thus, patients undergoing
central neck dissection also have a higher chance of
receiving treatment for subclinical micrometastatic disease
[2]. Indeed, prophylactic central neck dissection was found
to result in an increased use of radioactive 131I and, ultim-
ately, in more favorable outcomes [2]. Our results do not
confirm these data.
Many endocrine surgeons doubt that routine lymph
nodal dissection offers any real benefits to patients, ar-
guing that the procedure is associated with higher mor-
bidity, especially injury to the parathyroid glands (most
frequently the lower) [10,17,22], with rates of transient
hypoparathyroidism of 14 to 60%, permanent hypopara-
thyroidism of 3 to 11%, transient vocal cord paralysis of
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of 0 to 4% [16,19,27,29,40,41]. TT is associated with a
low morbidity rate, and thanks to radioiodine treatment
and TSH suppression therapy, the incidence of locore-
gional lymph node recurrence is low. The need for reop-
eration in the central compartment is uncommon, but it
is generally accepted that reoperations in the cervical
compartments are associated with greater risks of hypo-
parathyroidism and recurrent nerve palsy [1,24,42-44].
However, Kim et al. [45] reported a 0% incidence of new
recurrent laryngeal nerve palsy and a 0.4% incidence of
permanent hypoparathyroidism in a series of 20 patients
who underwent reoperation of the central lymph node
dissection for recurrent or persistent thyroid cancer;
data which have since been confirmed by other authors
[1,18] and in our experience. Reoperation (lymph node
dissection) is not usually associated with higher morbid-
ity, especially in cases of unilateral dissection, although
hypoparathyroidism and recurrent laryngeal nerve injury
have been observed in up to 14% and 9% of patients,
respectively [10].
The low rate (2.1%) of lymph node recurrence follow-
ing TT observed in the present study is in line with data
reported by others [10]. In the present study, analysis of
the recurrence patterns revealed that clinical recurrence
most commonly occurred at level III and IV in both
groups, regardless of central neck dissection. Interest-
ingly, only one central (VI) node recurrences was ob-
served, confirming that the absolute benefit of central
neck dissection may be small. Our results are in agree-
ment with other findings in the recent literature [46].
We did not observe any complications after reopera-
tions, likely because of the small number of patients
requiring a second surgical intervention.
The complication rates observed following prophylac-
tic central neck dissection (group B) are, in our experi-
ence, high: a transient or definitive hypoparathyroidism
was observed in 55 (25%) and 10 patients (4.54%), re-
spectively, in group A; while 25 (38.46%) and 7 patients
(10.76%) were diagnosed in group B, respectively (P = 0.049
and 0.117). Temporary recurrent laryngeal nerve paraly-
sis was observed in 3 patients in group A (1.36%) and in
2 patients in group B (3.07%) (P = 0.69). In particular,
the differences in the rate of transient hypoparathyr-
oidism were statistically significant while the inci-
dence of definitive hypoparathyroidism and temporary
recurrent laryngeal nerve paralysis are approximately
double in group B, even if the differences do not
reach statistical significance, probably because of the
limited number of cases.
To decrease the risk of postoperative complications
related to prophylactic central neck dissection, unilateral
central neck dissection has emerged as an alternative
approach to bilateral central neck dissection [20,25].Ipsilateral central neck dissection appears to be a safe,
efficacious, and interesting alternative to bilateral cen-
tral neck dissection, especially for small (≤1 cm) PTC,
but no conclusive data are available [2,10,22,25,29].
Nevertheless, a bilateral central neck dissection was per-
formed in all 65 cases of the present study, in view of the
risk of skip and contralateral metastases [47].
As a matter of fact, the recent American Thyroid Associ-
ation Guidelines, as well as a meta-analysis conducted by
Chisholm et al. [9], whilst taking into consideration all the
pros and cons, recommend routine central lymph node
dissection for all differentiated thyroid cancers, especially
in high-risk patients [10,22]. Prophylactic central neck dis-
section is not recommended for low-volume thyroid sur-
geons: the risk of nerve injury and hypocalcaemia appears
to be significantly greater for low-volume centers [2,41].
Of consequence, the current indications for perform-
ing a prophylactic central neck dissection are still a mat-
ter of debate. Our low recurrence rate (2.1%) combined
with the non-negligible incidence of complications (par-
ticularly transient and definitive hypoparathyroidism,
38.46% and 10.76% respectively) leads us to sustain that
prophylactic central lymph node dissection should not
be carried out on a routine basis in the treatment of
PTC. Instead, it may be more useful to develop criteria
for the identification of high risk patients for whom cen-
tral neck dissection could be of benefit. The incidence of
recurrence depends on numerous factors, such as tumor
size, patient age, sex (males are more disposed to recur-
rence), and extra-capsular spread [2,9,22,42]. In our
study, tumor histology was strongly associated with risk
of recurrence: Hürthle cell-variant (11.11%) and, in par-
ticular, tall cell-variant (16.66%) carcinomas were associ-
ated with a high risk of relapse (P = 0.001). Multifocality
(6.25%, P = 0.009) and extrathyroidal invasion (6.84%,
P = 0.005) also presented a higher risk of recurrence, in
line with other reports in the literature [2,9,22]. We
found no differences in relation to age or gender, while
smaller tumors were at lower risk of recurrence, in
agreement with other reports in the literature [2,9,22].
Moreover, 20% patients presented microcarcinomas
(tumors ≤ 1 cm in diameter) with low risk of recurrence,
a rate that is again in agreement with the literature [48].
The problem that remains is how to define the assess-
ment criteria of high-risk patients, considering the fact
that only the size of the tumor can be assessed preopera-
tively, while the type and the histological characteristics
(that is locoregional infiltration and multifocality) can
usually only be identified after surgery. We believe that a
prophylactic central neck dissection should not be rou-
tinely recommended for smaller tumors (≤1 cm) while it
may be advisable for larger tumors (>2 cm), especially if
cytological suspicion of a high risk subtype arises or if
there are intraoperative signs of extra-capsular spread. A
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could prove useful in better defining the high-risk popu-
lation. For example, patients with RET/PTC oncogene
expression have a higher rate of lymph node metastases
[49], and this could constitute a useful factor to consider
in the future. The development of techniques for the
intraoperative identification of metastatic lymph nodes
could also help the surgeon in this difficult choice.
Conclusions
The role of prophylactic central lymph node dissection
in the management of PTC remains controversial. There
is no convincing evidence that prophylactic central neck
dissection leads to an improvement in recurrence rate,
overall survival, or any clinically significant variable when
applied indiscriminately to all PTC patients. The recur-
rence rate found in this study of 2.1% confirms the rarity
of lymph node recurrence and leaves many doubts regard-
ing the usefulness of prophylactic central neck dissection.
The lateral neck was mainly involved in recurrence
regardless of initial central neck dissection, suggesting the
clinical benefit of central neck dissection may be small.
Our study confirms that prophylactic central neck
dissection is associated with increased morbidity, even
when performed by experienced surgeons: in particular,
it is associated with a higher rate of transient complica-
tions, mostly hypoparathyroidism.
Therefore, in our opinion, until conclusive evidence
emerges of the actual benefit of prophylactic central
neck dissection procedure in the treatment of PTC
without suspicious enlarged nodes, it may be avoided.
In conclusion, TT appears to be an adequate treatment
for clinically node-negative PTC. Prophylactic central
neck dissection could be considered for the more appro-
priate selection of patients for radioiodine treatment and
should be reserved for high-risk patients only. Unfortu-
nately, no clinical or pathological factors are able to pre-
dict with any certainty the presence of nodal metastasis.
However, in our experience, tumor size is related to an
increased risk of recurrence, as are some histological
types (Hürthle cell and, particularly, tall cell-variant),
multifocality, and locoregional infiltration.
The potential use of molecular markers will hopefully
offer a further strategy to stratify the risk of recurrence
in patients with PTC and allow a more tailored approach
to offer prophylactic central neck dissection to patients
with the greatest benefit. Multi-institutional larger stud-
ies with longer follow-up periods are necessary to draw
definitive conclusions.
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